Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis

Justin Sharim, Randy Tashjian, Nima Golzy, Nader Pouratian

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Glioblastoma is an uncommon and aggressive primary brain tumor with incidence of 3 per 100,000 annually. We report a 50-year-old woman diagnosed with glioblastoma within three years of induction of fingolimod therapy for relapsing-remitting multiple sclerosis. Fingolimod, an immunomodulating agent used in the treatment of relapsing-remitting multiple sclerosis, has also been suggested to impart a cardioprotective role in heart failure and arrhythmia via activation of P21-activated kinase-1 (Pak1). In the brain, Pak1 activation has been shown to correlate with decreased survival time amongst patients with glioblastoma. A molecular mechanism underlying a link between fingolimod use and glioblastoma development may involve activation of Pak1. To our knowledge, this is the first report of a potential association between fingolimod use and glioblastoma development.

Original languageEnglish (US)
Pages (from-to)166-168
Number of pages3
JournalJournal of Clinical Neuroscience
StatePublished - Aug 1 2016
Externally publishedYes


  • Fingolimod
  • Glioblastoma
  • P21-activated kinase

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)


Dive into the research topics of 'Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this